Navigation Links
Dendreon Corp. (Nasdaq: DNDN) - Prostate Cancer Patients Benefit
Date:4/30/2009

VALLEY COTTAGE, N.Y., April 30 /PRNewswire/ -- Less than two weeks ago, early on April 15th, Stock Preacher, in their Stock Talk section, posted a Special Technical Report on Dendreon Corporation (Nasdaq: DNDN), which we have been watching since 2007, when we first learned about it.

On April 14, DNDN gapped open on positive news from the previous day's close of 7.30/shr, to 16.00/shr, ran to 22.00/shr and closed at 16.99/shr + 9.69 (132%) on 65,345,600/shrs on the day, and since has traded as high as 27.00/shr over the past several trading sessions. From a technical POV, DNDN has traded down to close the gap it posted on the opening on April 14. This is very positive and Bullish action.

When we go back to look at the Stock Talk coverage, the Red Roadmaster's analysis after the April 14, 2009 market action was overall Bullish: in the near term Very Bullish, mid-term Bullish, and long term Bullish.

That analysis has proven to be true and the shares are having a dramatic run here, with overhead resistance Nil, and strong underlying support 21.40.

Yesterday,(April 29, 2009) DNDN closed + 11.13/shr (95%) at 23.00 on 48,134,768/shrs., the high on the day was 27.00/.

Late Tuesday afternoon, the Company released data from a Phase III clinical study that showed Provenge extended the lives of men with advanced prostate cancer by an average of 4.1 months. According to published analysts, Dendreon should be able to file for regulatory approval during the Q-4 Y 2009, with possible approval during the first half of 2010.

This is Dendreon Corp (DNDN): Dendreon is developing therapeutic vaccines that boost the body's immune system to help it fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its lead candidate is Provenge, a therapeutic vaccine that targets prostate cancer. Dendreon is also working on a therapeutic vaccine called Neuvenge as a treatment for breast, colon, ovarian, and kidney cancers; and it has research programs investigating cancer-fighting monoclonal antibodies and small molecule drugs. Its partners for its antibody programs include Amgen and Genentech

For more updates on Dendreon Corp (Nasdaq: DNDN), and other Companies making news, visit us at http://StockPreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a wholly owned entity of Allan James Group, Inc., a financial public relations firm. Please read our report and visit our website, StockPreacher.com, for complete risks and disclosures.

Investors can view all of the daily updates for free by visiting: http://StockPreacher.com/

Julio Serrano of Stock Preacher is a member of the National Association of Securities Dealers, CRD number 1603068.


'/>"/>
SOURCE Stock Preacher
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. -Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET-
2. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
3. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
4. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
5. Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine
6. ComPsych(R) Corp. Announces Health at Work(SM) Award Winners: Sprint, Erie Insurance, City of Naperville and Green Hills Public Library
7. New Health Corp. Announces the Addition of Hannaford Bros., Kash N Karry and Sweet Bay Supermarkets to its Retail Outlets
8. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
9. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
10. Former State Representative Terry Parke Joins Secure Services Corp.
11. InstaCare Corp. Reviewing M&A Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... The Visiting Nurse Association of ... R. Bard Foundation, Inc. to support the music therapy program offered at ... the nonprofit home care agency. Using evidence-based methods, professionally trained and certified music ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... Tears® EyeMist®, the signature product of her research center at Bio-Logic Aqua Research® ... largest population and the greatest number of sufferers of blindness. “We think that ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... repair a torn anterior cruciate ligament (ACL) offer patients improved quality of life ... Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The ...
(Date:7/20/2017)... Va. (PRWEB) , ... July 20, 2017 , ... ... McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief Medical ... Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... manufacturing network, the Company will be ceasing operations and ... Huntsville, Alabama . The closure of the facilities ... to 18 months. The Huntsville ... products and these restructuring actions are intended to better ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
Breaking Medicine Technology: